Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
15 Oct 2022
15 Oct 2022
Historique:
received:
08
04
2022
accepted:
22
09
2022
entrez:
15
10
2022
pubmed:
16
10
2022
medline:
16
10
2022
Statut:
epublish
Résumé
Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to generate infectious negative-strand RNA viruses on the basis of viral genomes encoded on plasmid DNA in the 1990s, paved the way to generate recombinant, vaccine strain-derived MeVs. These live-attenuated vaccine constructs can encode and express additional foreign antigens during transient virus replication following immunization. Effective humoral and cellular immune responses are induced not only against the MeV vector, but also against the foreign antigen cargo in immunized individuals, which can protect against the associated pathogen. This review aims to present an overview of the versatility of this vaccine vector as platform technology to target various diseases, as well as current research and developmental stages, with one vaccine candidate ready to enter phase III clinical trials to gain marketing authorization, MV-CHIK.
Identifiants
pubmed: 36243743
doi: 10.1038/s41541-022-00543-4
pii: 10.1038/s41541-022-00543-4
pmc: PMC9568972
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
119Subventions
Organisme : Bundesministerium für Gesundheit (Federal Ministry of Health, Germany)
ID : Charis 6a
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : MU2327-6/1
Organisme : Deutsches Zentrum für Infektionsforschung (German Center for Infection Research)
ID : HZI2021Z38
Informations de copyright
© 2022. The Author(s).
Références
Sci Transl Med. 2021 Jun 9;13(597):
pubmed: 34108251
Sci Rep. 2017 Sep 20;7(1):12017
pubmed: 28931922
EMBO J. 1987 Mar;6(3):681-8
pubmed: 3582370
Trends Microbiol. 1994 Sep;2(9):312-8
pubmed: 7529121
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32657-32666
pubmed: 33257540
Virology. 2014 Mar;452-453:32-41
pubmed: 24606680
Microbiol Immunol. 2016 Jul;60(7):501-5
pubmed: 27278100
Hum Vaccin Immunother. 2016 Jul 2;12(7):1678-89
pubmed: 26901482
Vaccine. 2012 Sep 7;30(41):5991-8
pubmed: 22732429
Microbiol Immunol. 2018 Feb;62(2):132-136
pubmed: 29194753
Vaccines (Basel). 2020 Mar 27;8(2):
pubmed: 32230902
J Infect Dis. 2005 Jan 15;191(2):207-14
pubmed: 15609230
Nat Biotechnol. 2012 Jul 10;30(7):658-70
pubmed: 22781695
Antiviral Res. 2018 Nov;159:63-67
pubmed: 30261226
Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec;385(12):1211-25
pubmed: 22983013
Virology. 2009 May 25;388(1):191-203
pubmed: 19345390
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):
pubmed: 33688034
PLoS One. 2012;7(11):e50397
pubmed: 23226275
Lancet Infect Dis. 2015 May;15(5):519-27
pubmed: 25739878
Nature. 2000 Aug 24;406(6798):893-7
pubmed: 10972291
EMBO J. 1994 Sep 15;13(18):4195-203
pubmed: 7925265
Vaccine. 2011 Feb 4;29(7):1481-90
pubmed: 21185852
Vaccine. 2016 Sep 7;34(39):4724-4731
pubmed: 27523740
J Virol. 2003 Nov;77(21):11546-54
pubmed: 14557640
Cancer Immunol Immunother. 2019 Apr;68(4):533-544
pubmed: 30656384
Virology. 2008 Jun 5;375(2):321-30
pubmed: 18374960
EMBO J. 1995 Dec 1;14(23):5773-84
pubmed: 8846771
J Infect Dis. 2019 Jul 31;220(5):735-742
pubmed: 31053842
J Gen Virol. 1999 Jan;80 ( Pt 1):101-106
pubmed: 9934691
J Virol. 2007 Mar;81(6):2564-72
pubmed: 17182683
JCI Insight. 2021 Nov 8;6(21):
pubmed: 34582377
Methods Mol Biol. 2017;1581:151-168
pubmed: 28374248
J Virol. 1993 Oct;67(10):6025-32
pubmed: 8371352
Front Immunol. 2020 Mar 31;11:546
pubmed: 32300346
Pediatr Infect Dis J. 1996 Jan;15(1):62-6
pubmed: 8684879
Virology. 2008 Mar 30;373(1):39-50
pubmed: 18155263
PLoS One. 2016 Mar 01;11(3):e0150213
pubmed: 26930411
MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34
pubmed: 23760231
J Infect Dis. 2020 Feb 18;221(5):721-728
pubmed: 31580436
J Exp Med. 2008 Nov 24;205(12):2717-25
pubmed: 18981239
J Virol. 2009 Nov;83(22):11645-54
pubmed: 19726516
NPJ Vaccines. 2022 Apr 19;7(1):43
pubmed: 35440656
Curr Opin Virol. 2020 Apr;41:85-97
pubmed: 32861945
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669275
J Virol. 1999 Nov;73(11):9568-75
pubmed: 10516065
Epidemiol Rev. 2019 Jan 31;41(1):28-33
pubmed: 31673694
NPJ Vaccines. 2021 Oct 22;6(1):123
pubmed: 34686669
Vaccine. 2013 Aug 12;31(36):3718-25
pubmed: 23742993
J Virol. 2007 Oct;81(19):10597-605
pubmed: 17634218
J Virol. 2009 Sep;83(17):9013-7
pubmed: 19535451
J Infect Dis. 2012 Jul 15;206(2):212-9
pubmed: 22551814
Sci Transl Med. 2020 Apr 1;12(537):
pubmed: 32238577
Sci Transl Med. 2019 Oct 2;11(512):
pubmed: 31578242
Virology. 2018 Nov;524:151-159
pubmed: 30199752
J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S420-S428
pubmed: 34590128
Vaccine. 2013 Dec 9;31(51):6079-86
pubmed: 24161574
Vaccine. 2010 Sep 24;28(41):6730-9
pubmed: 20688034
NPJ Vaccines. 2019 Feb 27;4:12
pubmed: 30820355
J Virol. 2015 Nov;89(22):11654-67
pubmed: 26355094
J Virol. 2012 Mar;86(6):3027-37
pubmed: 22238320
EBioMedicine. 2022 Jan;75:103811
pubmed: 35042081
Vaccine. 2014 Jul 31;32(35):4529-4536
pubmed: 24951869
PLoS One. 2013;8(3):e58414
pubmed: 23516477
Science. 2020 Jun 19;368(6497):1367-1370
pubmed: 32554594
J Virol. 2007 Dec;81(23):12816-26
pubmed: 17881453
Vaccines (Basel). 2015 Jul 03;3(3):503-18
pubmed: 26350592
Lancet. 2019 Dec 22;392(10165):2718-2727
pubmed: 30409443
Lancet. 2008 Nov 29;372(9653):1881-1893
pubmed: 19012954
Vaccine. 2011 Feb 11;29(8):1710-20
pubmed: 21182995
Curr Top Microbiol Immunol. 2009;330:151-71
pubmed: 19203109
Sci Rep. 2017 Dec 4;7(1):16892
pubmed: 29203786
Virology. 2018 Jun 11;521:99-107
pubmed: 29902727
Vaccine. 2009 May 26;27(25-26):3385-90
pubmed: 19200837
Lancet. 2015 Oct 31;386(10005):1735-6
pubmed: 26545433
Vaccines (Basel). 2019 Mar 04;7(1):
pubmed: 30836661
Vaccine. 2001 Mar 21;19(17-19):2329-36
pubmed: 11257357
PLoS Negl Trop Dis. 2007 Dec 12;1(3):e96
pubmed: 18160988
Vaccine. 2005 Aug 22;23(36):4463-72
pubmed: 15993518
Vaccine. 2007 Apr 20;25(16):2974-83
pubmed: 17303293
EBioMedicine. 2022 Jan;75:103810
pubmed: 35045362
Nat Med. 2010 Mar;16(3):334-8
pubmed: 20111039
J Virol. 2004 Jan;78(1):146-57
pubmed: 14671096
J Virol. 2012 Nov;86(21):11558-66
pubmed: 22896607
Mol Ther Oncolytics. 2020 Sep 23;19:136-148
pubmed: 33145397
J Gen Virol. 2016 Sep;97(9):2117-2128
pubmed: 27311834
Nat Commun. 2021 Nov 1;12(1):6277
pubmed: 34725327
J Virol. 1999 Jun;73(6):4823-8
pubmed: 10233943
Vaccine. 2009 May 26;27(25-26):3299-305
pubmed: 19200842
J Virol. 2019 Jan 17;93(3):
pubmed: 30429338
Vaccine. 2008 Apr 16;26(17):2164-74
pubmed: 18346823
Nature. 2011 Nov 02;480(7378):530-3
pubmed: 22048310
Open Virol J. 2012;6:12-22
pubmed: 22383906
Comp Immunol Microbiol Infect Dis. 2010 Dec;33(6):e81-8
pubmed: 20299097
J Virol. 2015 Feb;89(4):2192-200
pubmed: 25473055
J Infect Dis. 2011 Jul;204 Suppl 1:S533-48
pubmed: 21666210
J Infect Dis. 2020 Apr 27;221(10):1713-1723
pubmed: 31828322
Sci Rep. 2018 Oct 24;8(1):15701
pubmed: 30356097